Hui Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hui Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Tao Li
Department of General Surgery, QiLu Hospital, Shandong University, Jinan, Shandong, China
4 shared publications - Dongxu Wang
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, PR China
3 shared publications - Zhao-Ru Dong
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
3 shared publications - Han Li
Department of General Surgery, Qilu Hospital of Shandong University, 107 West Wen Hua Road, Jinan, 250012, China
2 shared publications - Lun-Jie Yan
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China
2 shared publications Peng Fu
Department of Nephrology, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Yangpu District
2 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1865521
Association between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies
Background: Considerable evidence suggests that hepatocellular carcinoma (HCC) is tightly related to metabolic disorders. However, it is not yet clear which metabolic risk factors play a critical role in hepatocarcinogenesis. Methods: We searched Pubmed, Embase, and Web of Science from inception up to April 29, 2023. The hazard ratio (HR) and the corresponding 95% confidence interval (95%CI) were used to assess the pooled risk. Results: Seventy-three studies involving more than 45 million participants were included. Among the metabolic risk factors: metabolic syndrome (MetS) (HR = 1.80, 95%CI: 1.44–2.25), diabetes mellitus (DM) (HR = 2.01, 95%CI: 1.79–2.27), body mass index (BMI) ≥ 24 kg/m 2 (HR = 1.47, 95%CI: 1.35–1.61), waist circumference (WC) (HR = 1.39, 95%CI: 1.26–1.55), waist-to-hip ratio (WHR) (HR = 1.33, 95%CI: 1.16–1.52), waist-to-height ratio (WHtR) (HR = 2.23, 95%CI: 1.42–3.51), reduced triglyceride (TG) (HR = 1.36, 95%CI: 1.09–1.69) and hypertension (HR = 1.43, 95%CI: 1.13–1.81) were positively associated with HCC risk. The disturbances of high-density lipoprotein cholesterol (HDL-C) levels (elevated, HR = 0.88, 95%CI: 0.81–0.96; reduced, HR = 0.96, 95%CI: 0.93–0.99) and elevated low-density lipoprotein cholesterol (LDL-C) (HR = 0.44, 95%CI: 0.32–0.62) were consistently associated with decreased risk of HCC. Nevertheless, elevated total cholesterol (TC) (HR = 0.87, 95%CI: 0.69–1.10) and elevated TG (HR = 0.72, 95%CI: 0.36–1.43) were not significantly associated with HCC risk. Conclusion: Adverse metabolic risk factors are associated with an increased risk of HCC, which may provide new insights into HCC screening strategies for patients with these risk factors. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023401883 .
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1865521
Open AccessAssociation between metabolic risk factors and hepatocellular carcinoma: a systematic review and meta-analysis of cohort studies
Background: Considerable evidence suggests that hepatocellular carcinoma (HCC) is tightly related to metabolic disorders. However, it is not yet clear which metabolic risk factors play a critical role in hepatocarcinogenesis. Methods: We searched Pubmed, Embase, and Web of Science from inception up to April 29, 2023. The hazard ratio (HR) and the corresponding 95% confidence interval (95%CI) were used to assess the pooled risk. Results: Seventy-three studies involving more than 45 million participants were included. Among the metabolic risk factors: metabolic syndrome (MetS) (HR = 1.80, 95%CI: 1.44–2.25), diabetes mellitus (DM) (HR = 2.01, 95%CI: 1.79–2.27), body mass index (BMI) ≥ 24 kg/m 2 (HR = 1.47, 95%CI: 1.35–1.61), waist circumference (WC) (HR = 1.39, 95%CI: 1.26–1.55), waist-to-hip ratio (WHR) (HR = 1.33, 95%CI: 1.16–1.52), waist-to-height ratio (WHtR) (HR = 2.23, 95%CI: 1.42–3.51), reduced triglyceride (TG) (HR = 1.36, 95%CI: 1.09–1.69) and hypertension (HR = 1.43, 95%CI: 1.13–1.81) were positively associated with HCC risk. The disturbances of high-density lipoprotein cholesterol (HDL-C) levels (elevated, HR = 0.88, 95%CI: 0.81–0.96; reduced, HR = 0.96, 95%CI: 0.93–0.99) and elevated low-density lipoprotein cholesterol (LDL-C) (HR = 0.44, 95%CI: 0.32–0.62) were consistently associated with decreased risk of HCC. Nevertheless, elevated total cholesterol (TC) (HR = 0.87, 95%CI: 0.69–1.10) and elevated TG (HR = 0.72, 95%CI: 0.36–1.43) were not significantly associated with HCC risk. Conclusion: Adverse metabolic risk factors are associated with an increased risk of HCC, which may provide new insights into HCC screening strategies for patients with these risk factors. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023401883 .
- Open Access
- 27 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
The prognostic significance of pretreatment systemic immune-inflammation index and prognostic nutritional index in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Background: Systemic immune-inflammation index (SII) and Prognostic nutritional index (PNI) are emerging inflammation-related indicators that have previously been linked to prognosis of cancer patients, but the results have been inconsistent. This meta-analysis aims to review and report the latest data regarding the prognostic value of the SII and PNI in cancer patients treated with immune checkpoint inhibitors (ICIs). Methods: We searched the relevant literature in PubMed, Cochrane Library, and Embase databases from inception to February 15, 2026. Meta-analyses were performed for overall survival (OS) and progression-free survival (PFS) to assess the prognostic role of SII and PNI in cancer patients treated with ICIs. The pooled OS and PFS were estimated using hazard ratios (HR) with 95% confidence intervals (95% CI) by the random-effects model. Subgroup analysis was also conducted to investigate the correlation between indicators and study features. Results: A total of 27 studies comprising 4000 patients treated with ICIs were included in this meta-analysis. In terms of the results based on multivariate analysis, the pooled results revealed that high SII level was an unfavorable predictor for OS (HR = 2.42, 95% CI = 1.88–3.10) and PFS (HR = 1.99, 95% CI = 1.36–2.90). In addition, lower level of PNI was correlated with worse OS (HR = 2.28, 95% CI = 1.68–3.08), as well as PFS (HR = 1.84, 95% CI = 1.56–2.17). Furthermore, subgroup analysis was conducted, and we found similar conclusions. Conclusion: Our findings support SII and PNI as promising biomarkers for adequately studied cancer types, but extending them to all malignancies requires prospective validation in less-studied cancers.
- 27 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessThe prognostic significance of pretreatment systemic immune-inflammation index and prognostic nutritional index in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Background: Systemic immune-inflammation index (SII) and Prognostic nutritional index (PNI) are emerging inflammation-related indicators that have previously been linked to prognosis of cancer patients, but the results have been inconsistent. This meta-analysis aims to review and report the latest data regarding the prognostic value of the SII and PNI in cancer patients treated with immune checkpoint inhibitors (ICIs). Methods: We searched the relevant literature in PubMed, Cochrane Library, and Embase databases from inception to February 15, 2026. Meta-analyses were performed for overall survival (OS) and progression-free survival (PFS) to assess the prognostic role of SII and PNI in cancer patients treated with ICIs. The pooled OS and PFS were estimated using hazard ratios (HR) with 95% confidence intervals (95% CI) by the random-effects model. Subgroup analysis was also conducted to investigate the correlation between indicators and study features. Results: A total of 27 studies comprising 4000 patients treated with ICIs were included in this meta-analysis. In terms of the results based on multivariate analysis, the pooled results revealed that high SII level was an unfavorable predictor for OS (HR = 2.42, 95% CI = 1.88–3.10) and PFS (HR = 1.99, 95% CI = 1.36–2.90). In addition, lower level of PNI was correlated with worse OS (HR = 2.28, 95% CI = 1.68–3.08), as well as PFS (HR = 1.84, 95% CI = 1.56–2.17). Furthermore, subgroup analysis was conducted, and we found similar conclusions. Conclusion: Our findings support SII and PNI as promising biomarkers for adequately studied cancer types, but extending them to all malignancies requires prospective validation in less-studied cancers.
- 30 April 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (8) , 1464-1475
Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis
Background and Aim: The purpose of the current study was to investigate the predictive value of hepatitis B core‐related antigen (HBcrAg) on the occurrence and recurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).Methods: We searched PubMed, Embase, Scopus, and Web of Science from database inception to April 6, 2023. Pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was calculated for the occurrence and recurrence of HCC.Results: Of the 464 articles considered, 18 articles recruiting 10 320 patients were included. The pooled results showed that high serum HBcrAg level was an independent risk factor for the occurrence of HCC in CHB patients (adjusted HR = 3.12, 95% CI: 2.40–4.06, P < 0.001, I2 = 43.2%, P = 0.043; OR = 5.65, 95% CI: 3.44–5.82, P < 0.001, I2 = 0.00%, P = 0.42). Further subgroup analysis demonstrated that the predictive ability of HBcrAg for the occurrence of HCC is not influenced by the hepatitis B e antigen (HBeAg) status or the use of nucleoside/nucleotide analogs (NAs). In addition, our meta‐analysis also suggests that HBcrAg is a predictor of HCC recurrence (adjusted HR = 1.71, 95% CI: 1.26–2.32, P < 0.001, I2 = 7.89%, P = 0.031).Conclusions: For patients with CHB, serum HBcrAg may be a potential predictive factor for the occurrence of HCC, regardless of HBeAg status or NA treatment. It may also serve as a novel prognostic biomarker for the recurrence of HCC. More studies are needed to confirm our conclusions.
- 30 April 2024
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 39 (8) , 1464-1475
Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis
Background and Aim: The purpose of the current study was to investigate the predictive value of hepatitis B core‐related antigen (HBcrAg) on the occurrence and recurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).Methods: We searched PubMed, Embase, Scopus, and Web of Science from database inception to April 6, 2023. Pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was calculated for the occurrence and recurrence of HCC.Results: Of the 464 articles considered, 18 articles recruiting 10 320 patients were included. The pooled results showed that high serum HBcrAg level was an independent risk factor for the occurrence of HCC in CHB patients (adjusted HR = 3.12, 95% CI: 2.40–4.06, P < 0.001, I2 = 43.2%, P = 0.043; OR = 5.65, 95% CI: 3.44–5.82, P < 0.001, I2 = 0.00%, P = 0.42). Further subgroup analysis demonstrated that the predictive ability of HBcrAg for the occurrence of HCC is not influenced by the hepatitis B e antigen (HBeAg) status or the use of nucleoside/nucleotide analogs (NAs). In addition, our meta‐analysis also suggests that HBcrAg is a predictor of HCC recurrence (adjusted HR = 1.71, 95% CI: 1.26–2.32, P < 0.001, I2 = 7.89%, P = 0.031).Conclusions: For patients with CHB, serum HBcrAg may be a potential predictive factor for the occurrence of HCC, regardless of HBeAg status or NA treatment. It may also serve as a novel prognostic biomarker for the recurrence of HCC. More studies are needed to confirm our conclusions.
- Open Access
- 21 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (6) , 3707-3722
Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances
The landscape of current tumor treatment has been revolutionized by the advent of immunotherapy based on PD-1/PD-L1 inhibitors. Leveraging its capacity to mobilize systemic antitumor immunity, which is primarily mediated by T cells, there is growing exploration and expansion of its potential value in various stages of clinical tumor treatment. Neoadjuvant immunotherapy induces a robust immune response against tumors prior to surgery, effectively facilitating tumor volume reduction, early eradication or suppression of tumor cell activity, and control of potential metastatic spread, to improve curative surgical resection rates, and prevent tumor recurrence. This review delineates the theoretical basis of neoadjuvant immunotherapy from preclinical research evidence, discusses specific challenges in clinical application, and provides a comprehensive overview of clinical research progress in neoadjuvant immunotherapy for gastrointestinal tumors. These findings suggest that neoadjuvant immunotherapy has the potential to ameliorate immunosuppressive states and enhance cytotoxic T cell function while preserving lymphatic drainage in the preoperative period. However, further investigations are needed on specific treatment regimens, suitable patient populations, and measurable endpoints. Despite numerous studies demonstrating the promising efficacy and manageable adverse events of neoadjuvant immunotherapy in gastrointestinal tumors, the availability of high-quality randomized controlled trials is limited, which highlights the necessity for further research.
- 21 March 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (6) , 3707-3722
Open AccessNeoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances
The landscape of current tumor treatment has been revolutionized by the advent of immunotherapy based on PD-1/PD-L1 inhibitors. Leveraging its capacity to mobilize systemic antitumor immunity, which is primarily mediated by T cells, there is growing exploration and expansion of its potential value in various stages of clinical tumor treatment. Neoadjuvant immunotherapy induces a robust immune response against tumors prior to surgery, effectively facilitating tumor volume reduction, early eradication or suppression of tumor cell activity, and control of potential metastatic spread, to improve curative surgical resection rates, and prevent tumor recurrence. This review delineates the theoretical basis of neoadjuvant immunotherapy from preclinical research evidence, discusses specific challenges in clinical application, and provides a comprehensive overview of clinical research progress in neoadjuvant immunotherapy for gastrointestinal tumors. These findings suggest that neoadjuvant immunotherapy has the potential to ameliorate immunosuppressive states and enhance cytotoxic T cell function while preserving lymphatic drainage in the preoperative period. However, further investigations are needed on specific treatment regimens, suitable patient populations, and measurable endpoints. Despite numerous studies demonstrating the promising efficacy and manageable adverse events of neoadjuvant immunotherapy in gastrointestinal tumors, the availability of high-quality randomized controlled trials is limited, which highlights the necessity for further research.
- 13 December 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , E144-E145
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
An abstract is unavailable. This article is available as a PDF only.
- 13 December 2023
- Published by Wolters Kluwer Health in Hepatology
- Vol. 79 (5) , E144-E145
Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
An abstract is unavailable. This article is available as a PDF only.
- 29 June 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (5) , 1993-2008
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line treatment in various types of previously untreatable malignancies, while limited evidence is available on the management of hepatitis B virus (HBV) in patients undergoing immunotherapy. We systematically reviewed data concerning challenges of hepatic adverse events including HBV reactivation and hepatitis in patients with chronic HBV infection undergoing immunotherapy. Methods A systematic search was conducted in Medline, web of science, Embase and Cochrane library up to May 31, 2022. Studies reporting the safety profile of ICIs in patients with HBV infection were eligible. Meta-analyses were conducted to generate odds ratios (ORs) with 95% confidence intervals (CIs). Results A total of 13 studies including 2561 patients were included for meta-analysis. The overall incidence rates of HBV reactivation in patients with chronic HBV infection and past HBV infection were 1.0% (95% CI 0–3%) and 0% (95% CI 0–0%), respectively. Among patients with chronic HBV infection, the incidence rates of HBV reactivation were 1.0% (95% CI 0–2%) and 10.0% (95% CI 4–18%) for patients with and without antiviral prophylaxis, respectively. Patients with chronic HBV infection were at a higher risk of HBV reactivation compared with those with past HBV infection [OR = 8.69, 95% CI (2.16–34.99)]. Antiviral prophylaxis significantly reduced the risk of HBV reactivation [OR = 0.12, 95% CI (0.02–0.67)] and HBV-associated hepatitis [OR = 0.05, 95% CI (0.01–0.28)] in patients with chronic HBV infection. Conclusions Prophylactic antiviral therapy should be administered to patients with chronic HBV infection undergoing anticancer immunotherapy. Patients with past HBV infection are at lower risk of HBV reactivation compared with those with chronic HBV infection, they could be initiated with antiviral prophylaxis or monitored with the intent of on-demand antiviral therapy.
- 29 June 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (5) , 1993-2008
Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis
Purpose Immune checkpoint inhibitors (ICIs) have been explored as first-line treatment in various types of previously untreatable malignancies, while limited evidence is available on the management of hepatitis B virus (HBV) in patients undergoing immunotherapy. We systematically reviewed data concerning challenges of hepatic adverse events including HBV reactivation and hepatitis in patients with chronic HBV infection undergoing immunotherapy. Methods A systematic search was conducted in Medline, web of science, Embase and Cochrane library up to May 31, 2022. Studies reporting the safety profile of ICIs in patients with HBV infection were eligible. Meta-analyses were conducted to generate odds ratios (ORs) with 95% confidence intervals (CIs). Results A total of 13 studies including 2561 patients were included for meta-analysis. The overall incidence rates of HBV reactivation in patients with chronic HBV infection and past HBV infection were 1.0% (95% CI 0–3%) and 0% (95% CI 0–0%), respectively. Among patients with chronic HBV infection, the incidence rates of HBV reactivation were 1.0% (95% CI 0–2%) and 10.0% (95% CI 4–18%) for patients with and without antiviral prophylaxis, respectively. Patients with chronic HBV infection were at a higher risk of HBV reactivation compared with those with past HBV infection [OR = 8.69, 95% CI (2.16–34.99)]. Antiviral prophylaxis significantly reduced the risk of HBV reactivation [OR = 0.12, 95% CI (0.02–0.67)] and HBV-associated hepatitis [OR = 0.05, 95% CI (0.01–0.28)] in patients with chronic HBV infection. Conclusions Prophylactic antiviral therapy should be administered to patients with chronic HBV infection undergoing anticancer immunotherapy. Patients with past HBV infection are at lower risk of HBV reactivation compared with those with chronic HBV infection, they could be initiated with antiviral prophylaxis or monitored with the intent of on-demand antiviral therapy.
- Open Access
- 1 February 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 395-404
Circulating Complement C1q as a Novel Biomarker is Associated with the Occurrence and Development of COPD
Purpose: Increasing evidence has shown that the immune response interacts with the chronic inflammatory response and gives rise to the occurrence and development of COPD. Complement component 1q (C1q), as a subcomponent of the C1 complex, could be involved in innate and adaptive immunity. Our study aimed to investigate the relationship between C1q and the clinical characteristics of COPD subjects. Patients and Methods: Serum C1q levels were measured in 203 COPD subjects and 191 non-COPD controls. Correlations between C1q and the characteristics of COPD were analyzed using Spearman’s rho. Receiver operating curve (ROC) analysis was used to evaluate the threshold value in differentiating disease status. All 203 COPD subjects were followed up for 1 year for future acute exacerbations. Results: There were significant reductions in serum C1q levels in COPD subjects compared to non-COPD controls. Moreover, serum C1q levels were obviously positively correlated with the FEV1/FVC ratio and predicted FEV1% but had a weakly negative correlation with the %LAA-950 and the percentage of neutrophils in peripheral blood. Using a cutoff value of 137.150 mg/l as the boundary in ROC analysis, the sensitivity and specificity were 65.9% and 76.0%, respectively. The 1-year follow-up results showed that C1q levels less than 137.150 mg/l were negatively related to the time to the next severe exacerbation and the time to death. Conclusion: Circulating C1q levels may be a novel biomarker not only related to the pulmonary function of COPD but also having great potential to predict the risk of COPD deterioration in the future. However, further prospective trials are needed to clarify the influences of C1q on the pathogenesis of COPD.
- 1 February 2022
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 17, 395-404
Open AccessCirculating Complement C1q as a Novel Biomarker is Associated with the Occurrence and Development of COPD
Purpose: Increasing evidence has shown that the immune response interacts with the chronic inflammatory response and gives rise to the occurrence and development of COPD. Complement component 1q (C1q), as a subcomponent of the C1 complex, could be involved in innate and adaptive immunity. Our study aimed to investigate the relationship between C1q and the clinical characteristics of COPD subjects. Patients and Methods: Serum C1q levels were measured in 203 COPD subjects and 191 non-COPD controls. Correlations between C1q and the characteristics of COPD were analyzed using Spearman’s rho. Receiver operating curve (ROC) analysis was used to evaluate the threshold value in differentiating disease status. All 203 COPD subjects were followed up for 1 year for future acute exacerbations. Results: There were significant reductions in serum C1q levels in COPD subjects compared to non-COPD controls. Moreover, serum C1q levels were obviously positively correlated with the FEV1/FVC ratio and predicted FEV1% but had a weakly negative correlation with the %LAA-950 and the percentage of neutrophils in peripheral blood. Using a cutoff value of 137.150 mg/l as the boundary in ROC analysis, the sensitivity and specificity were 65.9% and 76.0%, respectively. The 1-year follow-up results showed that C1q levels less than 137.150 mg/l were negatively related to the time to the next severe exacerbation and the time to death. Conclusion: Circulating C1q levels may be a novel biomarker not only related to the pulmonary function of COPD but also having great potential to predict the risk of COPD deterioration in the future. However, further prospective trials are needed to clarify the influences of C1q on the pathogenesis of COPD.
- Open Access
- 24 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 58601-58610
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study
- 24 April 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 58601-58610
Open AccessEffect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study
Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study Effect of hepatic steatosis on the progression of chronic hepatitis B: A prospective cohort and in vitro study